A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis
A Phase IIb, 12 Week Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate Efficacy, Safety and Tolerability of Revamilast in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Sponsor: Glenmark Pharmaceuticals Ltd. India
Listed as NCT01430507, this PHASE2 trial focuses on Rheumatoid Arthritis and remains completed. Sponsored by Glenmark Pharmaceuticals Ltd. India, it has been updated 6 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Sep 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Glenmark Pharmaceuticals Ltd. India
- Glenmark Pharmaceuticals S.A.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ahmedabad, India, Bangalore, India, Bydgoszcz, Poland, Cebu, Philippines, Chennai, India, Chełm Śląski, Poland, Colombo, Sri Lanka, Częstochowa, Poland, Davao City, Philippines, Galle, Sri Lanka and 15 more location s